What is DRTS's current stock price?

DRTS (Alpha Tau Medical Ltd.) is currently trading at $10.04 with a market cap of $883.6M.

What sector is Alpha Tau Medical Ltd. in?

Alpha Tau Medical Ltd. (DRTS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is DRTS a good stock to buy?

Analysts have a Buy consensus on DRTS with a price target of $11.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

DRTS Alpha Tau Medical Ltd.

Healthcare

$10.04-8.39%ClosedMarket Cap: $883.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

12.99

P/S

0.00

EV/EBITDA

-19.27

DCF Value

$-0.02

FCF Yield

-3.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-73.2%

ROA

-52.3%

ROIC

-46.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-22.9M	$—
Q4 null	$0.00	$-12.1M	$—
FY null	$0.00	$-42.6M	$—
Q3 null	$0.00	$-11.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$11.50

Target (Median)

$11.50

Target Range

$8.00 - $15.00

0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-20

Piper SandlerNeutral

2026-05-19

Ladenburg ThalmannBuy

2026-05-12

CitigroupBuy

2026-03-11

HC Wainwright & Co.Buy

2026-03-10

Trading Activity

Insider Trades

View All

Avruch Michaeldirector

SellWed Mar 18

Avruch Michaeldirector

SellWed Mar 18

Avruch Michaeldirector

SellWed Mar 18

Avruch Michaeldirector

SellWed Mar 18

Avruch Michaeldirector

SellWed Mar 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.12

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Peers